Vanguard Group’s MAIA Biotechnology MAIA Stock Holding History

Vanguard Group’s Portfolio MAIA Stock Details MAIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$1.77M	Buy	1,154,833 +51,688	+5%	+$67.5K	﹤0.01%	3600
2025 Q3	$1.7M	Sell	1,103,145 -37,624	-3%	-$61.5K	﹤0.01%	3625
2025 Q2	$2.05M	Buy	1,140,769 +490,513	+75%	+$878K	﹤0.01%	3526
2025 Q1	$995K	Buy	650,256 +67,749	+12%	+$125K	﹤0.01%	3712
2024 Q4	$1.15M	Buy	582,507 +16,133	+3%	+$38.7K	﹤0.01%	3718
2024 Q3	$1.59M	Buy	566,374 +29,353	+5%	+$91.5K	﹤0.01%	3626
2024 Q2	$1.84M	Buy	537,021 +255,339	+91%	+$805K	﹤0.01%	3586
2024 Q1	$620K	Buy	281,682 +107,523	+62%	+$161K	﹤0.01%	3964
2023 Q4	$204K	Buy	174,159 +80,659	+86%	+$130K	﹤0.01%	4222
2023 Q3	$206K	Hold	93,500	–	–	﹤0.01%	4248
2023 Q2	$206K	Buy	+93,500	New	+$250K	﹤0.01%	4309

Other funds holding MAIA

CWM

Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

RWM

Ritholtz Wealth Management New York $5.76B AUM 24.57% 1-Year Est. Return

CAG

Centerpoint Advisory Group Overland Park, Kansas $158M AUM 26.37% 1-Year Est. Return

Vanguard Group's MAIA Position: Q4 2025 in Review

Vanguard Group increased its MAIA Biotechnology (MAIA) stake by 4.7% in Q4 2025, buying an estimated $67.5K and bringing the position to 1,154,833 shares worth $1.77M. The position accounts for ﹤0.01% of the portfolio, ranked #3600.

Vanguard Group first reported a position in MAIA in Q2 2023 and has held it in 11 quarters since. The position peaked at $2.05M in Q2 2025. 26 funds tracked by Wall St. Rank hold MAIA as of Q4 2025.

Vanguard Group held 1,154,833 shares of MAIA Biotechnology worth $1.77M as of Q4 2025.
Vanguard Group bought 51,688 MAIA Biotechnology shares in Q4 2025, an estimated $67.5K.
MAIA Biotechnology made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3600 holding.
Vanguard Group first reported a position in MAIA Biotechnology in Q2 2023 and has held it in 11 quarters since.
Vanguard Group's MAIA Biotechnology position peaked at $2.05M in Q2 2025.
26 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.